Welcome to our dedicated page for Opgen SEC filings (Ticker: OPGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OpGen Inc. (OPGN), now named CapForce Inc., files regulatory disclosures that document its corporate transition, governance matters and capital structure. The company's 8-K reports cover material definitive agreements, financing amendments, securities purchase arrangements, common-stock issuance terms, operating results and other material events.
Proxy materials describe shareholder voting matters and board-governance proposals. Capital-structure filings also reflect reverse stock split actions and security-structure disclosures as the issuer moved away from its former precision medicine diagnostics identity toward digital investment banking and financial technology.
CapForce Inc. (CFOR) reported another early-stage quarter with no revenue and a wider loss as it pivots into financial services and fintech. For the three months ended March 31, 2026, the company posted a net loss of $710,571, compared with $408,133 a year earlier, driven mainly by higher general and administrative costs.
Cash and cash equivalents fell to $78,586, with total cash and restricted cash of $380,848, so operations are expected to rely heavily on a committed equity facility with controlling shareholder AEI Capital, under which $6.5 million of capacity remained as of March 31, 2026. CapForce also holds a sizeable non‑controlling equity stake in a private client valued at $35.0 million, received as consideration for advisory work and subject to a make‑whole if the client’s planned IPO values the stake below that amount.
During the period, CapForce completed its transition from its former OpGen diagnostics business, finalized the iCapX acquisition (paid with 2,028,867 shares of common stock), launched a new 2026 stock incentive plan, and continued developing a digital investment banking and cap table management platform. Following Nasdaq’s prior delisting decision, the stock now trades on the OTC Markets Expert Market while the company’s appeal remains under review by the SEC.
CapForce Inc. (CFOR) reported another early-stage quarter with no revenue and a wider loss as it pivots into financial services and fintech. For the three months ended March 31, 2026, the company posted a net loss of $710,571, compared with $408,133 a year earlier, driven mainly by higher general and administrative costs.
Cash and cash equivalents fell to $78,586, with total cash and restricted cash of $380,848, so operations are expected to rely heavily on a committed equity facility with controlling shareholder AEI Capital, under which $6.5 million of capacity remained as of March 31, 2026. CapForce also holds a sizeable non‑controlling equity stake in a private client valued at $35.0 million, received as consideration for advisory work and subject to a make‑whole if the client’s planned IPO values the stake below that amount.
During the period, CapForce completed its transition from its former OpGen diagnostics business, finalized the iCapX acquisition (paid with 2,028,867 shares of common stock), launched a new 2026 stock incentive plan, and continued developing a digital investment banking and cap table management platform. Following Nasdaq’s prior delisting decision, the stock now trades on the OTC Markets Expert Market while the company’s appeal remains under review by the SEC.
CapForce Inc. files its annual report describing a full pivot from infectious disease diagnostics to a capital-markets-focused financial technology model. The company now offers listing sponsorship and consultancy services for Asian growth companies targeting IPOs and direct listings and is developing a digital investment banking and cap table platform.
In 2025 CapForce acquired Sun Investment Enterprises Limited, owner of Malaysian fintech iCapX, to anchor its cap table management and data analytics capabilities. Control shifted to AEI Capital Ltd., which owns about 76.1% of the common stock, while non-affiliates held voting stock with a market value of about $11.6 million at $4.78 per share as of June 30, 2025.
The business is in an early stage, with only one advisory client, minimal headcount, and operations concentrated in Malaysia and Singapore. The filing highlights numerous risks, including heavy reliance on a single client, complex multi-jurisdictional regulation, cybersecurity and data-privacy exposure, low trading liquidity on the OTC Expert Market, and potential dilution from outstanding warrants and stock options.
CapForce Inc. files its annual report describing a full pivot from infectious disease diagnostics to a capital-markets-focused financial technology model. The company now offers listing sponsorship and consultancy services for Asian growth companies targeting IPOs and direct listings and is developing a digital investment banking and cap table platform.
In 2025 CapForce acquired Sun Investment Enterprises Limited, owner of Malaysian fintech iCapX, to anchor its cap table management and data analytics capabilities. Control shifted to AEI Capital Ltd., which owns about 76.1% of the common stock, while non-affiliates held voting stock with a market value of about $11.6 million at $4.78 per share as of June 30, 2025.
The business is in an early stage, with only one advisory client, minimal headcount, and operations concentrated in Malaysia and Singapore. The filing highlights numerous risks, including heavy reliance on a single client, complex multi-jurisdictional regulation, cybersecurity and data-privacy exposure, low trading liquidity on the OTC Expert Market, and potential dilution from outstanding warrants and stock options.
CapForce Inc. filed a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 without unreasonable effort or expense. The delay stems from valuation and purchase price allocation work related to the company’s previously disclosed acquisition of iCapX Sdn. Bhd. and limited internal accounting resources. The company is completing its financial close and expects its Annual Report on Form 10-K for the year ended December 31, 2025 remains in process; the filing states the company anticipates significant changes in results for the quarter versus the prior-year period.
CapForce Inc. filed a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 without unreasonable effort or expense. The delay stems from valuation and purchase price allocation work related to the company’s previously disclosed acquisition of iCapX Sdn. Bhd. and limited internal accounting resources. The company is completing its financial close and expects its Annual Report on Form 10-K for the year ended December 31, 2025 remains in process; the filing states the company anticipates significant changes in results for the quarter versus the prior-year period.
CapForce Inc., formerly OpGen, Inc., reported results of its 2025 annual stockholder meeting and detailed a strategic rebranding toward fintech-enabled digital investment banking services. Stockholders approved changing the corporate name to CapForce Inc., and the Company expects its ticker to change to “CFOR.”
Investors also approved a new 2026 Incentive Compensation Plan reserving 1,000,000 shares, with an evergreen feature that can add 5% of outstanding common stock each year from 2027 through 2036, subject to Board discretion. Other proposals passed comfortably, including director elections, approval of warrant exercises for 889,274 shares, ratification of certain share sales to controlling stockholder AEI Capital, a say‑on‑pay advisory vote, and auditor ratification.
OpGen, Inc. is asking stockholders to vote at its virtual 2025 Annual Meeting on February 23, 2026. The agenda includes electing five directors, approving a new 2026 Equity Incentive Plan, and several key capital and governance items.
Stockholders are asked to approve the issuance of up to 889,274 shares of common stock upon exercise of warrants issued in a May 4, 2023 best‑efforts public offering, and to ratify the prior sale and issuance of 7,200,000 shares of common stock to AEI Capital Ltd. for purposes of Rule 16b‑3(d)(2). The Board also seeks approval to change the company name from “OpGen, Inc.” to “CapForce Inc.”, hold an advisory “say on pay” vote on executive compensation, and ratify Beckles & Co., Inc. as independent auditor for 2025.
As of the record date, there were 10,149,411 shares of common stock and 250 shares of Series D Convertible Preferred Stock outstanding, with each preferred share carrying 244.4 votes on an as‑converted basis. AEI Capital Ltd. beneficially owns 7,724,728 shares of common stock, or 75.65%, making the company a controlled company under Nasdaq rules.
OpGen, Inc. is asking stockholders to vote at its 2025 virtual annual meeting on February 23, 2026 on seven proposals.
Items include electing five directors, approving a new 2026 Equity Incentive Plan, and authorizing the issuance of up to 889,274 shares of common stock on exercise of warrants from a May 4, 2023 offering. Stockholders are also asked to ratify the prior sale of 7,200,000 common shares to AEI Capital Ltd. under Rule 16b-3(d)(2), approve changing the company name to CapForce Inc., give an advisory say-on-pay vote, and ratify Beckles & Co., Inc. as auditor for 2025.
As of December 31, 2025, 10,149,411 common shares and 250 shares of Series D Preferred Stock were outstanding, with AEI Capital Ltd. beneficially owning about 75.65% of the common stock, making OpGen a controlled company. The proxy describes an AEI-related assignment of advisory fees to CapForce and the stock-for-stock acquisition of iCapX, as well as leadership changes and equity-based consulting arrangements for key executives.
OpGen, Inc. reported that it acquired Sun Investment Enterprises Limited, a British Virgin Islands holding company that owns Malaysian fintech iCapX Sdn. Bhd., on December 1, 2025. iCapX operates a cap table management platform and provides related corporate advisory services.
OpGen agreed to pay a purchase price of $12,278,703.08, to be satisfied through the issuance of 2,028,867 shares of its common stock at $6.052 per share to AEI Capital Ltd., its controlling stockholder and the seller. As a result of the transaction, iCapX became an indirect, wholly owned subsidiary of OpGen.
After the acquisition closed, iCapX completed advisory services for a privately held client, earning an advisory fee of $80,000 plus common stock equal to 1.4% of the client’s outstanding equity, which OpGen estimates to be worth approximately $14 million. The share sale agreement includes customary representations, warranties and covenants, and OpGen notes that actual value received from the client may differ from its estimates.
OpGen, Inc. extended its existing equity financing arrangement with AEI Capital Ltd. The company originally entered a Securities Purchase Agreement allowing it to sell shares of common stock with an aggregate value of up to $3.0 million, later amended to permit two additional tranches of $3.0 million each, for a total of $9.0 million, and to extend sales through December 31, 2025. A new Supplemental Letter dated December 17, 2025 further extends OpGen’s ability to sell common stock under this agreement until December 31, 2026. These shares may be sold without registration in reliance on Section 4(a)(2) of the Securities Act and Regulations D and S as sales to accredited investors and under similar state law exemptions.
Separately, on December 18, 2025, David Lazar notified OpGen of his resignation as President, effective January 8, 2026. His resignation is stated not to result from any disagreement regarding the company’s operations, policies, or practices.
OpGen, Inc. announced a leadership change with the resignation of John Tan Honjian as Chief Executive Officer, while he continues to serve as Chairman of the Board. The company appointed Christian-Laurent Bonte as the new Chief Executive Officer of both OpGen and its wholly owned subsidiary, CapForce International Holdings Ltd.
Mr. Bonte, age 49, brings extensive investment banking and capital markets experience from roles in Hong Kong and Singapore, including positions at Meyzer Capital Management, Far Cap Pte Ltd, and ARC Capital Ltd. Under his promotion letter with CapForce, he will receive an initial annual base salary of $156,000, a guaranteed minimum annual bonus of $13,000, a performance bonus ranging from $26,000 to $312,000, eligibility for per-deal incentive payments, and an annual stock grant targeted at $200,000 based on performance.
OpGen, Inc. has pivoted from infectious disease diagnostics to financial services and fintech through its CapForce subsidiary, which provides listing sponsorship and consulting services. For the nine months ended September 30, 2025, OpGen generated $4,000,000 of revenue from a single international listing sponsorship client, but reported no revenue in Q3 2025.
The company posted Q3 2025 net loss of $608,730, yet remained profitable year-to-date with $2,493,129 of net income, driven by the new business line and tight operating expenses. At September 30, 2025, OpGen held $414,211 in cash and cash equivalents, $302,262 of restricted cash, a $5,000,000 equity investment in the client, and $4,043,838 of accounts receivable tied to that same relationship, while stockholders’ equity increased to $10,157,965 from $7,380,628 at year-end 2024.
Liquidity relies heavily on a financing arrangement with controlling stockholder AEI Capital Ltd., under which OpGen may sell up to an additional $7,000,000 of common stock through December 31, 2025; management believes this, together with current cash, can fund operations for more than 12 months. The company’s common stock was delisted from Nasdaq following failure to meet the stockholders’ equity listing standard and now trades on the OTC Markets Pink Limited Market under the symbol OPGN, and the business is highly concentrated, with one customer representing 99% of accounts receivable and 100% of 2025 year-to-date revenue.